Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)

British Journal of Cancer

Volumn 101, Issue 5, 2009, Pages 803-812

  Liu, W M ^a   Henry, J Y ^a   Meyer, B ^a   Bartlett, J B ^b   Dalgleish, A G ^a   Galustian, C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CELGENE CORPORATION   (United States)

Author keywords

Lenalidomide; Metastasis; Pomalidomide; Thalidomide; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LENALIDOMIDE; LEPTIN; MOLECULAR MARKER; POMALIDOMIDE; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR ALPHA; UVOMORULIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CARCINOMA CELL; CELL ANCHORAGE; CELL COUNT; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL TRANSFORMATION; COLONY FORMATION; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; IMMUNOMODULATION; LUNG METASTASIS; LUNG NODULE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; THALIDOMIDE; TUMOR CELLS, CULTURED;

EID: 70249135225     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605206     Document Type: Article

References (56)

1. Alley MC, Uhl CB, Lieber MM (1982) Improved detection of drug cytotoxicity in the soft agar colony formation assay through use of a metabolizable tetrazolium salt. Life Sci 31: 3071-3078
2. Aragon-Ching JB, Li H, Gardner ER, Figg WD (2007) Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Drug Discov 2: 167-174
3. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4: 314-322
4. Bartlett JB, Tozer A, Stirling D, Zeldis JB (2005) Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93: 613-619
5. Beck Jr L, D'Amore PA (1997) Vascular development: cellular and molecular regulation. FASEB J 11: 365-373
6. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloprotei-nase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744
7. Blansfield JA, Caragacianu D, Alexander III HR, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14: 270-280
8. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91: 1420-1424
9. Chanan-Khan AA, Cheson BD (2008) Lenalidomide for the treatment of B-Cell malignancies. J Clin Oncol 26: 1544-1552
10. Cifone MA, Fidler IJ (1980) Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci 77: 1039-1043
11. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163: 380-386
12. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C (2004) Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/ Tek and CD105 expression in breast cancer (n-905). Br J Cancer 90: 1216-1221
13. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91: 4082-4085
14. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cyto-toxicity in multiple myeloma. Blood 98: 210-216
15. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567
16. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma (010) Study Investigators (2007) Lenalidomide plus dexa-methasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132 (Pubitemid 350146107)
17. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69: 56-63
18. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87: 1166-1172
19. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
20. Freedman VH, Shin SI (1974) Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3: 355-359
21. Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG (2004) Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 4: 1963-1970
22. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58: 1033-1045
23. Gu Y, Li H, Miki J, Kim KH, Furusato B, Sesterhenn IA, Chu WS, McLeod DG, Srivastava S, Ewing CM, Isaacs WB, Rhim JS (2006) Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res 312: 831-843
24. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
25. Haslett PA, Hanekom WA, Muller G, Kaplan G (2003) Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187: 946-955
26. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128: 192-203
27. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2: 289-300
28. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR (1995) Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 154: 69-71
29. Kalmadi S, Davis M, Dowlati A, O'Keefe S, Cline-Burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T (2007) Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs 25: 211-216
30. Khanna C, Hunter K (2005) Modeling metastasis in vivo. Carcinogenesis 26: 513-523
31. Komorowski J, Jerczyńska H, Siejka A, Barańska P, Ławnicka H, Pawłowska Z, Stepień H (2006) Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci 78: 2558-2563
32. Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV (2004) Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18: 624-627
33. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
34. Liu W, Nizar S, Dalgleish A (2009a) Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer-a case study. Med Oncol (e-pub ahead of print 12 May 2009; doi:10.1007/s12032-009-9228-6)
35. Liu WM, Laux H, Henry J, Bolton T, Dalgleish A, Galustian C (2009b) A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Mol Biol Rep (e-pub ahead of print 14 July 2009; doi:10.1007/s11033-009- 9614-3)
36. Liu WM, Lawrence AJ, Joel SP (2002) The importance of drug scheduling and recovery phases in determining drug activity. Improving etoposide efficacy in BCR-ABL-positive CML cells. Eur J Cancer 38: 842-850
37. Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, Joel SP, Malpas JS (2004) s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J 5: 247-254
38. Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, Stirling DI, Libutti SK (2007) Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 5: 38
39. Melchert M, Kale V, List A (2007) The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 14: 123-129
40. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99: 4525-4530
41. Mustonen T, Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129: 895-898
42. Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403
43. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17: 197-203
44. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Bührer C, Henze G, Seeger K, Wellmann S (2006) The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 12: 5526-5532
45. Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne KJ, Dalgleish AG (2006) Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 42: 2318-2325
46. Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26: 25-35
47. Shin SI, Freedman VH, Risser R, Pollack R (1975) Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci 72: 4435-4439
48. Stirling D (2001) Thalidomide: a novel template for anticancer drugs. Semin Oncol 28: 602-606
49. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-Girona A, Muller GW, Brady HA, Chan KW (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 67: 746-755
50. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133-2142 (Pubitemid 350146108)
51. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409
52. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8
53. Wu A, Scheffler MR (2004) Multiple-dose pharmacokinetics and safety of CC-5013 in 15 multiple myeloma patients. J Clin Oncol 22: 2056
54. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14: 4650-4657
55. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248
56. Yuan A, Yang PC, Yu CJ, Lee YC, Yao YT, Chen CL, Lee LN, Kuo SH, Luh KT (1995) Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 152: 2157-2162